根治性膀胱切除术中盆腔淋巴结清扫的研究进展

蒋铭心; 牛亦农

doi:10.13201/j.issn.1001-1420.2024.06.014

根治性膀胱切除术中盆腔淋巴结清扫的研究进展

蒋铭心¹,
牛亦农^1, ,

- 首都医科大学附属北京友谊医院泌尿外科(北京，100050)

详细信息

通讯作者: 牛亦农，E-mail：niuyinong@mail.ccmu.edu.cn

中图分类号: R737.14

收稿日期: 2024-04-01

刊出日期: 2024-06-06

Research advances in pelvic lymph node dissection during radical cystectomy for bladder cancer

JIANG Mingxin¹,
NIU Yinong^1, ,

- Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, 100050, China

More Information

Corresponding author: NIU Yinong, E-mail: niuyinong@mail.ccmu.edu.cn

Received Date: 01 April 2024

Publish Date: 06 June 2024

摘要

摘要: 淋巴结转移是膀胱癌的主要转移类型，影响患者治疗方式的选择和预后的判断。肌层浸润性膀胱癌易发生淋巴结转移，根治性膀胱切除术加盆腔淋巴结清扫术是其标准治疗术式，但淋巴结清扫的范围一直存在争议。了解膀胱癌淋巴结清扫的研究进展，有助于做出最佳的临床决策。
- 膀胱癌 /
- 治疗 /
- 淋巴结转移 /
- 淋巴结清扫
Abstract: Lymph node metastasis is the main type of metastasis in bladder cancer, which affects the choice of treatment and prognosis of patients. Muscle-invasive bladder cancer is prone to lymph node metastasis, and radical cystectomy with pelvic lymph node dissection is the standard treatment procedure for it. However, the extent of lymph node dissection has been controversial. Understanding research advances in lymph node dissection for bladder cancer can help make the best clinical decisions.
- bladder cancer /
- treatment /
- lymph node metastasis /
- lymph node dissection

HTML全文

参考文献(46)

[1]	Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. doi: 10.3322/caac.21834
[2]	Abol-Enein H, El-Baz M, Abd El-Hameed MA, et al. Lymph node involvement in patients with bladder cancer treated with radical cystectomy: a patho-anatomical study: a single center experience[J]. J Urol, 2004, 172(5 Pt 1): 1818-1821.
[3]	Liedberg F, Chebil G, Davidsson T, et al. Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer[J]. J Urol, 2006, 175(1): 84-89. doi: 10.1016/S0022-5347(05)00066-2
[4]	Gschwend JE, Dahm P, Fair WR. Disease specific survival as endpoint of outcome for bladder cancer patients following radical cystectomy[J]. Eur Urol, 2002, 41(4): 440-448. doi: 10.1016/S0302-2838(02)00060-X
[5]	Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1, 054 patients[J]. J Clin Oncol, 2023, 41(22): 3772-3781. doi: 10.1200/JCO.22.02762
[6]	Alfred Witjes J, Max Bruins H, Carrión A, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2023 guidelines[J]. Eur Urol, 2024, 85(1): 17-31. doi: 10.1016/j.eururo.2023.08.016
[7]	Leissner J, Ghoneim MA, Abol-Enein H, et al. Extended radical lymphadenectomy in patients with urothelial bladder cancer: results of a prospective multicenter study[J]. J Urol, 2004, 171(1): 139-144. doi: 10.1097/01.ju.0000102302.26806.fb
[8]	Moschini M, Arbelaez E, Cornelius J, et al. Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer[J]. Urol Oncol, 2018, 36(6): 307. e9-307. e14. doi: 10.1016/j.urolonc.2018.03.002
[9]	Jensen JB, Ulhøi BP, Jensen KM. Lymph node mapping in patients with bladder cancer undergoing radical cystectomy and lymph node dissection to the level of the inferior mesenteric artery[J]. BJU Int, 2010, 106(2): 199-205. doi: 10.1111/j.1464-410X.2009.09118.x
[10]	May M, Protzel C, Vetterlein MW, et al. Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy?Results of the PROMETRICS 2011 database[J]. Int Urol Nephrol, 2017, 49(2): 247-254. doi: 10.1007/s11255-016-1469-7
[11]	Steven K, Poulsen AL. Radical cystectomy and extended pelvic lymphadenectomy: survival of patients with lymph node metastasis above the bifurcation of the common iliac vessels treated with surgery only[J]. J Urol, 2007, 178(4 Pt 1): 1218-1224.
[12]	Wang YC, Wu J, Dai B, et al. Extended versus non-extended lymphadenectomy during radical cystectomy for patients with bladder cancer: a meta-analysis of the effect on long-term and short-term outcomes[J]. World J Surg Oncol, 2019, 17(1): 225. doi: 10.1186/s12957-019-1759-5
[13]	Simone G, Papalia R, Ferriero M, et al. Stage-specific impact of extended versus standard pelvic lymph node dissection in radical cystectomy[J]. Int J Urol, 2013, 20(4): 390-397. doi: 10.1111/j.1442-2042.2012.03148.x
[14]	孟令全, 贺庆豹, 王明帅, 等. 腹腔镜下根治性膀胱切除术中扩大淋巴结清扫与标准淋巴结清扫的疗效比较[J]. 中华泌尿外科杂志, 2017, 38(5): 342-346. https://cdmd.cnki.com.cn/Article/CDMD-10760-1019046778.htm
[15]	王文宽, 王明帅, 宋黎明, 等. 根治性膀胱切除术中扩大淋巴结清扫与标准淋巴结清扫的疗效与预后生存分析比较[J]. 临床泌尿外科杂志, 2018, 33(11): 865-869. https://lcmw.whuhzzs.com/article/doi/10.13201/j.issn.1001-1420.2018.11.004
[16]	Bi LK, Huang H, Fan XX, et al. Extended vs non-extended pelvic lymph node dissection and their influence on recurrence-free survival in patients undergoing radical cystectomy for bladder cancer: a systematic review and meta-analysis of comparative studies[J]. BJU Int, 2014, 113(5b): E39-E48.
[17]	Gschwend JE, Heck MM, Lehmann J, et al. Extended versus limited lymph node dissection in bladder cancer patients undergoing radical cystectomy: survival results from a prospective, randomized trial[J]. Eur Urol, 2019, 75(4): 604-611. doi: 10.1016/j.eururo.2018.09.047
[18]	Katims AB, Bochner BH. Extended pelvic lymph node dissection in muscle invasive bladder cancer[J]. Curr Opin Urol, 2023, 33(4): 252-257. doi: 10.1097/MOU.0000000000001096
[19]	Zehnder P, Studer UE, Skinner EC, et al. Super extended versus extended pelvic lymph node dissection in patients undergoing radical cystectomy for bladder cancer: a comparative study[J]. J Urol, 2011, 186(4): 1261-1268. doi: 10.1016/j.juro.2011.06.004
[20]	Møller MK, Høyer S, Jensen JB. Extended versus superextended lymph-node dissection in radical cystectomy: subgroup analysis of possible recurrence-free survival benefit[J]. Scand J Urol, 2016, 50(3): 175-180. doi: 10.3109/21681805.2015.1132473
[21]	郝瀚, 吴鑫, 郑卫, 等. 膀胱尿路上皮癌淋巴结转移特点: 单中心522例膀胱根治性切除病例回顾[J]. 北京大学学报(医学版), 2014, 46(4): 524-527. https://www.cnki.com.cn/Article/CJFDTOTAL-BYDB201404008.htm
[22]	Crozier J, Papa N, Perera M, et al. Comparative sensitivity and specificity of imaging modalities in staging bladder cancer prior to radical cystectomy: a systematic review and meta-analysis[J]. World J Urol, 2019, 37(4): 667-690. doi: 10.1007/s00345-018-2439-8
[23]	Papalia R, Simone G, Grasso R, et al. Diffusion-weighted magnetic resonance imaging in patients selected for radical cystectomy: detection rate of pelvic lymph node metastases[J]. BJU Int, 2012, 109(7): 1031-1036. doi: 10.1111/j.1464-410X.2011.10446.x
[24]	Triantafyllou M, Studer UE, Birkhäuser FD, et al. Ultrasmall superparamagnetic particles of iron oxide allow for the detection of metastases in normal sized pelvic lymph nodes of patients with bladder and/or prostate cancer[J]. Eur J Cancer, 2013, 49(3): 616-624. doi: 10.1016/j.ejca.2012.09.034
[25]	Birkhäuser FD, Studer UE, Froehlich JM, et al. Combined ultrasmall superparamagnetic particles of iron oxide-enhanced and diffusion-weighted magnetic resonance imaging facilitates detection of metastases in normal-sized pelvic lymph nodes of patients with bladder and prostate cancer[J]. Eur Urol, 2013, 64(6): 953-960. doi: 10.1016/j.eururo.2013.07.032
[26]	Bacchiani M, Salamone V, Massaro E, et al. Assessing the performance of 18F-FDG PET/CT in bladder cancer: a narrative review of current evidence[J]. Cancers(Basel), 2023, 15(11): 2951.
[27]	Al-Zubaidi M, Ong K, Viswambaram P, et al. Comparing fluorodeoxyglucose positron emission tomography with computed tomography in staging for nodal and distant metastasis in urothelial/bladder cancer[J]. BJUI Compass, 2024, 5(4): 473-479. doi: 10.1002/bco2.304
[28]	Wu SX, Zheng JJ, Li Y, et al. A radiomics nomogram for the preoperative prediction of lymph node metastasis in bladder cancer[J]. Clin Cancer Res, 2017, 23(22): 6904-6911. doi: 10.1158/1078-0432.CCR-17-1510
[29]	Wu SX, Zheng JJ, Li Y, et al. Development and validation of an MRI-based radiomics signature for the preoperative prediction of lymph node metastasis in bladder cancer[J]. EBioMedicine, 2018, 34: 76-84. doi: 10.1016/j.ebiom.2018.07.029
[30]	Sun R, Zhang M, Yang L, et al. Preoperative CT-based deep learning radiomics model to predict lymph node metastasis and patient prognosis in bladder cancer: a two-center study[J]. Insights Imaging, 2024, 15(1): 21. doi: 10.1186/s13244-023-01569-5
[31]	Rahate NP, Kapse A, Rahate PV, et al. The wonder dye: uses and implications of indigocyanine green in various surgeries[J]. Cureus, 2023, 15(10): e46722.
[32]	Polom W, Markuszewski M, Cytawa W, et al. Fluorescent versus radioguided lymph node mapping in bladder cancer[J]. Clin Genitourin Cancer, 2017, 15(3): e405-e409. doi: 10.1016/j.clgc.2016.11.007
[33]	Rietbergen DDD, van Gennep EJ, KleinJan GH, et al. Evaluation of the hybrid tracer indocyanine green-99 m Tc-nanocolloid for sentinel node biopsy in bladder cancer-a prospective pilot study[J]. Clin Nucl Med, 2022, 47(9): 774-780. doi: 10.1097/RLU.0000000000004301
[34]	Kaczmarek K, Małkiewicz B, Lemiński A. Adequate pelvic lymph node dissection in radical cystectomy in the era of neoadjuvant chemotherapy: a meta-analysis and systematic review[J]. Cancers(Basel), 2023, 15(16): 4040.
[35]	Zennami K, Takahara K, Nukaya T, et al. The role of lymph node dissection in patients with muscle-invasive bladder cancer who underwent radical cystectomy following neoadjuvant chemotherapy[J]. Clin Genitourin Cancer, 2024, 22(2): 1-9. doi: 10.1016/j.clgc.2023.06.016
[36]	Nadal R, Valderrama BP, Bellmunt J. Progress in systemic therapy for advanced-stage urothelial carcinoma[J]. Nat Rev Clin Oncol, 2024, 21(1): 8-27. doi: 10.1038/s41571-023-00826-2
[37]	Fan ZR, Deng JP, Wang YT, et al. Bladder cancer: immunotherapy and pelvic lymph node dissection[J]. Vaccines(Basel), 2024, 12(2): 150.
[38]	Rahim MK, Okholm TLH, Jones KB, et al. Dynamic CD8⁺ T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes[J]. Cell, 2023, 186(6): 1127-1143. e18. doi: 10.1016/j.cell.2023.02.021
[39]	Xu ZY, Li ZZ, Cao LM, et al. Seizing the fate of lymph nodes in immunotherapy: To preserve or not?[J]. Cancer Lett, 2024, 588: 216740. doi: 10.1016/j.canlet.2024.216740
[40]	汪菲, 鲁华菲, 高向阳, 等. 液体活检在癌症筛查中的现状及展望[J]. 中华健康管理学杂志, 2022, 16(6): 411-423.
[41]	Liu WT, Qi L, Lv H, et al. MiRNA-141 and miRNA-200b are closely related to invasive ability and considered as decision-making biomarkers for the extent of PLND during cystectomy[J]. BMC Cancer, 2015, 15: 92. doi: 10.1186/s12885-015-1110-7
[42]	Chen CH, Luo YM, He W, et al. Exosomal long noncoding RNA LNMAT2 promotes lymphatic metastasis in bladder cancer[J]. J Clin Invest, 2020, 130(1): 404-421.
[43]	Chen X, Zhang JT, Ruan WM, et al. Urine DNA methylation assay enables early detection and recurrence monitoring for bladder cancer[J]. J Clin Invest, 2020, 130(12): 6278-6289.
[44]	Jordaens S, Oeyen E, Willems H, et al. Protein biomarker discovery studies on urinary sEV fractions separated with UF-SEC for the first diagnosis and detection of recurrence in bladder cancer patients[J]. Biomolecules, 2023, 13(6): 932.
[45]	Christensen E, Birkenkamp-Demtröder K, Sethi H, et al. Early detection of metastatic relapse and monitoring of therapeutic efficacy by ultra-deep sequencing of plasma cell-free DNA in patients with urothelial bladder carcinoma[J]. J Clin Oncol, 2019, 37(18): 1547-1557.
[46]	Xu Y, Gao ZP, Sun XY, et al. The role of circular RNA during the urological cancer metastasis: exploring regulatory mechanisms and potential therapeutic targets[J]. Cancer Metastasis Rev, 2024.